-
Sci Adv: A New Mechanism of Multiple Myeloma's Resistance to Immunomodulators
Time of Update: 2021-06-18
Teru Hideshima as co-first authors) published a titled ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow in Science Advances.
The paper described in detail the role and mechanism of ERK signaling pathway in myeloma drug resistance caused by the bone marrow microenvironment of multiple myeloma .
-
Deqi Pharmaceutical Partners Announces the Latest Clinical Data of Eltanexor in the Treatment of Myelodysplastic Syndrome
Time of Update: 2021-06-17
At present, Deqi Pharmaceuticals is carrying out clinical trials of eltanexor in the treatment of patients with MDS and advanced solid tumors in China.
-
The clinical advantage of APG-2575 is beginning to appear, the first domestic Bcl-2 inhibitor for CLL/SLL has unlimited prospects
Time of Update: 2021-06-16
Pre-clinical studies have shown that APG-2575 and BTK inhibitors have significant synergistic anti-tumor activity, and the clinical development of combined therapy is full of great potential .
-
Leukemia: Study on the effectiveness and safety of a new treatment strategy for ruxotinib in patients with myelofibrosis anemia
Time of Update: 2021-06-16
The REALIZE Phase 2 study (NCT02966353) aims to evaluate the effectiveness and safety of a new ruxolitinib treatment strategy , which requires lowering the starting dose and delaying the infusion time in patients with anemic MF .
-
Cell Death Differ: MLKL-mediated G-CSF release promotes myeloid differentiation in acute myeloid leukemia
Time of Update: 2021-06-16
MLKL can regulate myeloid differentiation in AML by mediating the release of G-CSF from leukemia progenitor cells .
MLKL can regulate myeloid differentiation in AML by mediating the release of G-CSF from leukemia progenitor cells .
-
JCEM: Correlation between plasma catecholamines and body weight and diabetes in patients with pheochromocytoma and paraganglioma
Time of Update: 2021-06-16
Norepinephrine and its metabolites in the plasma of PCC/PGL patients are directly related to HA1C, and there is a negative correlation between it and body weight .
-
BMJ: Patients with atrial fibrillation or mechanical heart valve implantation do not require anticoagulation and bridging treatment after invasive surgery
Time of Update: 2021-06-16
Studies have concluded that in patients with atrial fibrillation or mechanical heart valve implantation who interrupted warfarin anticoagulation therapy due to surgery, postoperative dalteparin sodium bridging has no significant effect on preventing the risk of major thrombosis .
-
Another large private hospital goes out of business!
Time of Update: 2021-06-12
Hebi Jingli Hospital was officially listed on the New Third Board as the first share of Zhongyuan Medical on October 17, 2016, becoming the first private hospital in Henan to land on the capital market.
-
Scientific research reveals: 4 potential mechanisms of mesenchymal stem cells in the treatment of premature ovarian failure
Time of Update: 2021-06-12
[5]Zhang Y, Xia X, Yan J, Yan L, Lu C, Zhu X, Wang T, Yin T, Li R, Chang HM, Qiao J.
[5]Zhang Y, Xia X, Yan J, Yan L, Lu C, Zhu X, Wang T, Yin T, Li R, Chang HM, Qiao J.
-
Postpone the approval of anti-cancer drugs!
Time of Update: 2021-06-12
However, former Xinji shareholders stated that one of the new CAR-T drugs, liso-cel, for the treatment of non-Hodgkin’s lymphoma, had not been approved by the FDA before December 31 last year, and the payment had disappeared out of thin air.
-
Recruitment of medical talents (06.04 update)
Time of Update: 2021-06-12
[Recruitment requirements] Have long-term development willingness, diligence and practicality, high interpersonal sensitivity, strong execution ability, and team spirit; experience in special medicine, cardiovascular and radiology fields is preferred; college degree or above, major in medicine .
-
Nature Sub-Journal: Single-base editor helps treat liver disease...
Time of Update: 2021-06-12
The use of lipid nanoparticles to achieve the delivery of ABE-encoding genes and a single guide RNA targeting PCSK9 (negative regulator of LDL), which can achieve up to 67% base editing (an average of 61%) level in mice, and in rhesus monkeys Editing efficiency of up to 34% (26% on average) can also be achieved.
-
To "turn" mutant proteins into healthy proteins, Liu Ruqian's team's latest "Nature" brings new breakthroughs in gene therapy
Time of Update: 2021-06-11
Using the single-base editing method, the team provides a new idea for gene therapy, which is expected to open up a whole new world of rare genetic disease treatment.
-
Express Selective JAK Inhibitor Receives FDA Priority Review Eligibility for Treatment of Myelofibrosis
Time of Update: 2021-06-11
▎Editor of WuXi AppTec content team On June 1, 2021, CTI BioPharma announced that the US FDA has accepted its new drug application (NDA) submitted for the investigational oral kinase inhibitor pacritinib for the treatment of bone marrow with severe thrombocytopenia Fibrosis (myelofibrosis) patients.
-
[EHA First Look] An overview of the academic progress of Roche's blood R&D pipeline
Time of Update: 2021-06-11
The results of the two studies announced at this year's EHA meeting continue to confirm the efficacy of the Pola-BR regimen, and other combination treatment regimens based on pola (Pola-R-Len) are also expected to help more DLBCL patients to be cured.
-
Nature is working hard again!
Time of Update: 2021-06-11
Liu (Liu Ruqian) of the Broad Institute and other teams published a research paper titled "Base editing of haematopoietic stem cells rescues sickle cell disease in mice" in Nature online, which used a customized gland The purine base editor (ABE8e-NRCH) converts the SCD allele (HBBS) to Makassar β-globin (HBBG), which is a non-pathogenic variant.
-
JCO: Arsenic combined with all-trans retinoic acid can safely and effectively treat Chinese APL pediatric patients!
Time of Update: 2021-06-10
With the application of all-trans retinoic acid (ATRA) combined with chemotherapy or arsenic trioxide (ATO), APL has become a curable disease , with a complete remission rate of 90-100% in clinical trials.
-
Head-to-head superiority data unveiled!
Time of Update: 2021-06-06
Studies have shown that Zebutinib has achieved the superiority of the objective response rate (ORR) and achieved significant progress-free survival (PFS) benefits.
The interim analysis of this head-to-head study showed that Zebutinib has achieved significant improvements in efficacy and safety compared to Ibrutinib.
-
Cell breakthrough: Scientists have found a new fat burning pathway with long-lasting potential...
Time of Update: 2021-06-06
Moreover, the BAT activation mediated by GPR3 in the human body is also independent of the β-adrenergic receptor-mediated pathway, and enhancing the expression of GPR3 is sufficient to promote the consumption of white fat.
-
Yingli Pharmaceutical's PI3Kδ inhibitor has obtained three FDA orphan drug qualifications
Time of Update: 2021-06-06
On May 28, Yingli Pharmaceuticals announced that the US FDA officially granted its PI3Kδ inhibitor linpris tablets (YY-20394) a new orphan drug designation for the treatment of patients with T-cell lymphoma.
[1]New progress|Yingli Pharmaceutical Limpris tablets (YY-20394) obtained another FDA orphan drug qualification.
